Comparative Pharmacology
Head-to-head clinical analysis: ORALONE versus UCERIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORALONE versus UCERIS.
ORALONE vs UCERIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ORALONE is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory cytokines.
Uceris (budesonide) is a corticosteroid with potent glucocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines (e.g., IL-1, IL-2, IL-4, IL-5, TNF-alpha), suppression of arachidonic acid metabolism via phospholipase A2 inhibition, and reduction of inflammatory cell infiltration. It has high topical anti-inflammatory activity and undergoes extensive first-pass hepatic metabolism, minimizing systemic bioavailability.
0.3-0.6 mg/kg IV/IM every 4-6 hours as needed; maximum single dose 30 mg.
For induction of remission in mild to moderate active ulcerative colitis: one 9 mg extended-release tablet orally once daily for up to 8 weeks.
None Documented
None Documented
1.5–3 hours (mean 2.5 hours) in adults; prolonged to 3–6 hours in hepatic impairment and up to 4 hours in elderly patients.
2.8-4.5 hours (terminal). Clinical context: short half-life supports once-daily extended-release formulation for colonic delivery.
Renal: >90% as glucuronide conjugates and unchanged drug (approximately 60% as metabolites, 30% unchanged). Biliary/fecal: <5%.
Renal: <1%. Fecal: approximately 63% as budesonide and metabolites. Biliary: minor.
Category C
Category C
Corticosteroid
Corticosteroid